Picture of Dice Therapeutics logo

DICE Dice Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid Cap

Momentum

Relative Strength (%)
1m-4.88%
3m+29.26%
6m+31.31%
1yr+152.11%
Volume Change (%)
10d/3m-10.25%
Price vs... (%)
52w High-0.51%
50d MA+17.53%
200d MA+39.49%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-18.11%
Return on Equity-21.6%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Dice Therapeutics EPS forecast chart

Profile Summary

DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    March 31st, 2023
    Incorporated
    November 5th, 2014
    Public Since
    July 27th, 2021
    No. of Shareholders
    27
    No. of Employees
    81
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    47,730,577

    DICE Share Price Performance

    Upcoming Events for DICE

    Q2 2023 Dice Therapeutics Inc Earnings Release

    Q3 2023 Dice Therapeutics Inc Earnings Release

    Similar to DICE

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of AcelRx Pharmaceuticals logo

    AcelRx Pharmaceuticals

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Acrivon Therapeutics logo

    Acrivon Therapeutics

    us flag iconNASDAQ Global Market

    Picture of Adagene logo

    Adagene

    us flag iconNASDAQ Global Market

    FAQ